Sun Pharma Advanced Research Company Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/8ff6zwnz4aph2fii8dhil3vu.pdf

Key Takeaways


PROSEEK: The Binary Event

Raghavan: "You can have clear validation of this hypothesis. You can also have a clear debunking of this hypothesis, but there's also a lot of gray space in between."

Partnership Strategy

Raghavan: "We would like to have a relationship which maintain some level of participation in both development and also commercialization of this program, plus some flexibility in terms of additional indications retained within SPARC."

Regulatory Pathway & Phase-III Design


Risks Explicitly Flagged by Management


Beyond Parkinson's: Pipeline Optionality

Raghavan: "If we go back several years that was the bet that we have taken in that neurodegeneration in spite of conventional wisdom going the other way, we believe that the neurodegeneration is an area is maturing from a science standpoint and that has also been validated recently with several transactions happening in this space."

Guidance & Commitments

CommitmentSpecificsTimeline
Interim analysis readoutBlinded data shared internally; limited partner engagement begins under CDALate March - early April 2024
Full top-line data disclosureITT population data availableAugust - September 2024
End-of-Phase-II meetingsWith USFDA and other global regulatory agenciesShortly after August-September 2024 data
Phase-III initiationMinimize lag from end of Phase-II; requires agency agreement on registrational studiesPost end-of-Phase-II meetings
Partnership executionInitiate conversations post-interim; aim to conclude with a partner for late-stage development and commercializationEngagement begins March-April 2024; conclusion may extend beyond September 2024
Long-term extension studyContinue in parallel with Phase-III planningOngoing
Additional preclinical workToxicity studies (e.g., carcinogenicity), drug-drug interaction studies for registrational packagePre-Phase-III initiation

Key Metrics

MetricQ3 FY24
PROSEEK enrollment513 patients globally, against a target of 506 evaluable patients
Interim analysis patient count441 patients, representing 85%-86% of enrolled patients
Interim analysis timingLate March-early April 2024
Full top line data expectedAugust-September 2024
PROSEEK study power~80%, with 500-plus patients
Part-I to Part-II rollover rate85% to 87% of eligible patients continuing into long-term extension
Vodobatinib dosing arms384 mg (top dose) and 192 mg (lower dose), 168 patients each, against placebo
Part-II extension study duration40 weeks (~10 months), with Part-A and Part-B combined for almost 80 weeks
Enrollment completionOctober 2023, with dosing having started in early 2020
IP coverage for VodobatinibLate second half of 2030s
Next FDA interaction on PROSEEKPost full data disclosure in September 2024
Full data set patient count513 patients, expected in early September 2024